View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Gerresheimer Group
24 September 2020

Development and Production of the Respimat® Reuseable Inhaler Housing Module

Boehringer Ingelheim commissioned Gerresheimer to develop and produce on a large scale the housing module for the new generation of Respimat® inhalers. This environmentally-friendly successor model to the established Respimat® inhaler can be successively loaded with up to six active agent cartridges, thus ensuring less waste and a considerably reduced CO2 footprint during the product life cycle. Gerresheimer has developed the housing module for the new inhaler and built the pre-series and series moulds, as well as the pre-series and series special-purpose machines. Gerresheimer is also carrying out the large series production.

Respimat® is an inhaler for the treatment of respiratory diseases firmly established in the market. Patients with chronic lung diseases like COPD use bronchodilation drugs on a daily basis to relieve their illnesses. Correspondingly high is the consumption of inhalers, which usually need to be replaced when the active agent has been exhausted. Boehringer Ingelheim has therefore decided to develop a new, reusable version of the Respimat®. This further development of the inhaler takes the feedback of patients into account. Thus, with a view to the ergonomics of the Respimat®, the grip has been further improved by an extension of the housing. The readability of the dosage display has also been improved.

Challenging for product development and industrialization was the necessity the new inhaler be immediately available in large numbers for its market launch. Gerresheimer, therefore, had to immediately transition from the development phase to a robust, high-volume, series production. To meet such a demanding schedule, the development phase and the creation of the equipment for large series production were advanced simultaneously. The foundation was first established with low-cavity moulds and semi-automated processes, on the basis of which the development of high-cavity moulds and completely automated processes for high-volume, large series production were immediately commenced with. In this way, the development of the series equipment is initiated ten months prior to the planned design verification. Also decisive for the success of the project was the availability of our own cleanroom production for small series, with which samples could be promptly tested under real conditions.

A risk-based approach that ensures the systematic mastering of all risks of the production process was used for the jump to large series production. Due to this robust development approach, all functional tests for the design verification of the low-cavity moulds and later for the implementation of the high-cavity series moulds were passed immediately. High-volume series production has also been running for several months now without problems.

For more information, please fill out the enquiry form attached to this page.

Gerresheimer is a leading global partner to the pharma and healthcare industry. With specialty glass and plastic products, the Company contributes to health and well-being....
Gerresheimer is one of the leading specialists for the production of high-quality glass and plastic products for the international pharmaceutical and healthcare industry.
During the Covid-19 pandemic, Gerresheimer is focusing on aspects including business continuity, customer demand, and supply chain. In 2019, we paved the way for profitable...
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology